(S (NP (ADJP (NNP De) (FW novo)) (JJ therapeutic) (NN design)) (VP (VBZ is) (VP (VBN challenged) (PP (IN by) (NP (NP (DT a) (JJ vast) (NN chemical) (NN repertoire)) (CC and) (NP (NP (JJ multiple) (NNS constraints)) (PP (JJ such) (IN as) (NP (NP (JJ high) (JJ broad-spectrum) (NN potency)) (CC and) (NP (JJ low) (NN toxicity))))))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (NNP CLaSS)) (PRN (-LRB- -LRB-) (NP (NNP Controlled) (NNP Latent) (NN attribute) (NNP Space) (NNP Sampling)) (-RRB- -RRB-)) (: -) (NP (NP (DT a) (ADJP (NN novel) (CC and) (JJ efficient)) (JJ computational) (NN method)) (PP (IN for) (NP (NP (JJ attribute-controlled) (NN generation)) (PP (IN of) (NP (NNS molecules))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ leverages) (NP (NP (NN guidance)) (PP (IN from) (NP (NP (NNS classifiers)) (VP (VBN trained) (PP (IN on) (NP (NP (DT an) (JJ informative) (NN latent) (NN space)) (PP (IN of) (NP (NNS molecules))) (VP (VBN modeled) (S (VP (VBG using) (NP (DT a) (JJ deep) (JJ generative) (NN autoencoder))))))))))))))))) (. .))
(S (NP (PRP We)) (ADVP (VBP further)) (VP (VB screen) (NP (DT the) (JJ generated) (NNS molecules)) (PP (IN by) (S (VP (VBG using) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (JJ deep) (VBG learning) (NNS classifiers)))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (JJ novel) (JJ physicochemical) (NNS features)) (VP (VBN derived) (PP (IN from) (NP (JJ high-throughput) (JJ molecular) (NNS simulations)))))))))))) (. .))
(S (NP (DT The) (VBN proposed) (NN approach)) (VP (VBZ is) (VP (VBN employed) (PP (IN for) (S (VP (VBG designing) (NP (NP (JJ non-toxic) (JJ antimicrobial) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NNP AMPs)) (-RRB- -RRB-)) (PP (IN with) (NP (JJ strong) (JJ broad-spectrum) (NN potency))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (VBG emerging) (NN drug) (NNS candidates)) (PP (IN for) (S (VP (VBG tackling) (NP (JJ antibiotic) (NN resistance))))))))))))))) (. .))
(S (NP (NP (NP (NN Synthesis)) (CC and) (NP (NN wet) (NN lab) (NN testing))) (PP (IN of) (NP (QP (JJ only) (NN twenty)) (VBN designed) (NNS sequences)))) (VP (VBN identified) (NP (NP (CD two) (ADJP (JJ novel) (CC and) (JJ minimalist)) (NNP AMPs)) (PP (IN with) (NP (NP (NP (JJ high) (NN potency)) (PP (IN against) (NP (NP (JJ diverse) (ADJP (JJ Gram-positive) (CC and) (JJ Gram-negative)) (NNS pathogens)) (, ,) (PP (VBG including) (NP (DT the) (JJ hard-to-treat) (JJ multidrug-resistant) (NNP K.) (NN pneumoniae))) (, ,)))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ low) (UCP (IN in) (NN vitro) (CC and) (IN in) (JJ vivo)) (NN toxicity)))))) (. .))
(S (NP (DT The) (VBN proposed) (NN approach)) (ADVP (RB thus)) (VP (VBZ presents) (NP (NP (DT a) (JJ viable) (NN path)) (PP (IN for) (NP (NP (JJR faster) (NN discovery)) (PP (IN of) (NP (ADJP (NN potent) (CC and) (JJ selective)) (NN broad-spectrum) (NNS antimicrobials))) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN success) (NN rate)) (PP (IN than) (NP (JJ state-of-the-art) (NNS methods))))))))) (. .))
